

Return of Organization Exempt From Income Tax

Under section 501(c), 527, or 4947(a)(1) of the Internal Revenue Code (except black lung benefit trust or private foundation)

Department of the Treasury Internal Revenue Service

The organization may have to use a copy of this return to satisfy state reporting requirements

A For the 2002 calendar year, or tax year period beginning and ending


B Check if applicable. C Name of organization THE CENTER FOR THE IMPROVEMENT OF HUMAN FUNCTIONING INTERNATIONAL, INC. D Employer identification number 48-0840415 E Telephone number 316-682-3100 F Accounting method X Cash

G Web site WWW.BRIGHTSPOT.ORG J Organization type X 501(c)(3)

K Check here if the organization's gross receipts are normally not more than \$25,000. L Gross receipts Add lines 6b, 8b, 9b, and 10b to line 12 4,260,112.68

Part I Revenue, Expenses, and Changes in Net Assets or Fund Balances

Table with 21 rows detailing Revenue (lines 1-12) and Expenses (lines 13-21). Includes sub-rows for public support, investment income, and inventory. Total revenue is 4,260,112.68 and total expenses is 4,428,993.68.



FILED JUN 18 '03

THE CENTER FOR THE IMPROVEMENT OF HUMAN
FUNCTIONING INTERNATIONAL, INC.

48-0840415

Part II Statement of Functional Expenses

All organizations must complete column (A) Columns (B), (C), and (D) are required for section 501(c)(3) and (4) organizations and section 4947(a)(1) nonexempt charitable trusts but optional for others

Do not include amounts reported on line 6b, 8b, 9b, 10b, or 16 of Part I		(A) Total	(B) Program services	(C) Management and general	(D) Fundraising	
22	Grants and allocations (attach schedule)					
	cash \$ _____ noncash \$ _____					
23	Specific assistance to individuals (attach schedule)					
24	Benefits paid to or for members (attach schedule)					
25	Compensation of officers, directors, etc	200,000.36	189,113.66	6,317.77	4,568.93	
26	Other salaries and wages	1,809,575.29	1,488,750.96	301,155.37	19,668.96	
27	Pension plan contributions					
28	Other employee benefits	85,307.23	66,676.29	17,030.79	1,600.15	
29	Payroll taxes	143,009.84	117,748.48	23,511.82	1,749.54	
30	Professional fundraising fees					
31	Accounting fees					
32	Legal fees					
33	Supplies	731,743.19	709,769.67	20,131.98	1,841.54	
34	Telephone	23,282.79	18,454.54	4,561.71	266.54	
35	Postage and shipping	47,195.67	32,404.05	9,967.64	4,823.98	
36	Occupancy	54,942.69	51,154.56	3,282.24	505.89	
37	Equipment rental and maintenance	96,810.83	54,027.73	42,514.47	268.63	
38	Printing and publications	32,711.33	25,010.71	4,663.96	3,036.66	
39	Travel					
40	Conferences, conventions, and meetings					
41	Interest					
42	Depreciation, depletion, etc (attach schedule)	363,576.50	332,795.81	25,073.01	5,707.68	
43	Other expenses not covered above (itemize)					
	a _____	43a				
	b _____	43b				
	c _____	43c				
	d _____	43d				
	e SEE STATEMENT 2	43e	840,837.96	753,033.04	68,937.04	18,867.88
44	Total functional expenses (add lines 22 through 43) Organizations completing columns (B)-(D) carry these totals to lines 13-15	4,428,993.68	3,838,939.50	527,147.80	62,906.38	

Joint Costs Check if you are following SOP 98-2

Are any joint costs from a combined educational campaign and fundraising solicitation reported in (B) Program services? Yes No

If "Yes," enter (i) the aggregate amount of these joint costs \$ _____ (ii) the amount allocated to Program services \$ _____

(iii) the amount allocated to Management and general \$ _____ and (iv) the amount allocated to Fundraising \$ _____

Part III Statement of Program Service Accomplishments

What is the organization's primary exempt purpose?

MEDICAL RESEARCH AND EDUCATION - SEE SCHEDULE 1

All organizations must describe their exempt purpose achievements in a clear and concise manner. State the number of clients served, publications issued, etc. Discuss achievements that are not measurable (Section 501(c)(3) and (4) organizations and 4947(a)(1) nonexempt charitable trusts must also enter the amount of grants and allocations to others)

Program Service Expenses
(Required for 501(c)(3) and (4) orgs and 4947(a)(1) trusts but optional for others)

a	SEE SCHEDULE 1				
		(Grants and allocations \$ _____)			3,838,939.50
b					
		(Grants and allocations \$ _____)			
c					
		(Grants and allocations \$ _____)			
d					
		(Grants and allocations \$ _____)			
e	Other program services (attach schedule)	(Grants and allocations \$ _____)			
f	Total of Program Service Expenses (should equal line 44, column (B), Program services)				3,838,939.50

Part IV Balance Sheets

Note Where required, attached schedules and amounts within the description column should be for end-of-year amounts only

		(A) Beginning of year	(B) End of year
Assets	45 Cash - non-interest-bearing		45
	46 Savings and temporary cash investments	2,776,302.96	46 2,675,552.77
	47 a Accounts receivable	47a	
	b Less allowance for doubtful accounts	47b	47c
	48 a Pledges receivable	48a	
	b Less allowance for doubtful accounts	48b	48c
	49 Grants receivable		49
	50 Receivables from officers, directors, trustees, and key employees		50
	51 a Other notes and loans receivable	51a	
	b Less allowance for doubtful accounts	51b	51c
	52 Inventories for sale or use		52
	53 Prepaid expenses and deferred charges		53
	54 Investments - securities	<input type="checkbox"/> Cost <input type="checkbox"/> FMV	54
	55 a Investments - land, buildings, and equipment basis	55a	
	b Less accumulated depreciation	55b	55c
56 Investments - other	SEE STATEMENT 3	1,580,694.43	56 1,340,126.76
57 a Land, buildings, and equipment basis	57a 7,780,925.20		
b Less accumulated depreciation	57b 5,893,409.66	1,969,115.45	57c 1,887,515.54
58 Other assets (describe <input type="checkbox"/> SEE STATEMENT 4)		1,881.88	58 3,639.53
59 Total assets (add lines 45 through 58) (must equal line 74)		6,327,994.72	59 5,906,834.60
Liabilities	60 Accounts payable and accrued expenses		60
	61 Grants payable		61
	62 Deferred revenue		62
	63 Loans from officers, directors, trustees, and key employees		63
	64 a Tax-exempt bond liabilities		64a
	b Mortgages and other notes payable		64b
	65 Other liabilities (describe <input type="checkbox"/> FLEX. HOLDING ACCOUNT)		6,914.35
66 Total liabilities (add lines 60 through 65)		6,914.35	66 7,132.69
Net Assets or Fund Balances	Organizations that follow SFAS 117, check here <input checked="" type="checkbox"/> and complete lines 67 through 69 and lines 73 and 74		
	67 Unrestricted	5,309,194.00	67 5,071,320.02
	68 Temporarily restricted	40,437.00	68 0.00
	69 Permanently restricted	971,449.37	69 828,381.89
	Organizations that do not follow SFAS 117, check here <input type="checkbox"/> and complete lines 70 through 74		
	70 Capital stock, trust principal, or current funds		70
	71 Paid-in or capital surplus, or land building, and equipment fund		71
	72 Retained earnings endowment accumulated income, or other funds		72
73 Total net assets or fund balances (add lines 67 through 69 or lines 70 through 72, column (A) must equal line 19, column (B) must equal line 21)		6,321,080.37	73 5,899,701.91
74 Total liabilities and net assets / fund balances (add lines 66 and 73)		6,327,994.72	74 5,906,834.60

Form 990 is available for public inspection and, for some people, serves as the primary or sole source of information about a particular organization. How the public perceives an organization in such cases may be determined by the information presented on its return. Therefore, please make sure the return is complete and accurate and fully describes, in Part III the organization's programs and accomplishments.

Part VII Analysis of Income-Producing Activities (See page 31 of the instructions)

	Unrelated business income		Excluded by section 512 513 or 514		(E) Related or exempt function income
	(A) Business code	(B) Amount	(C) Exclu- sion code	(D) Amount	
93 Program service revenue					
a VARIOUS PATIENT FEES					1,479,907.07
b REGISTRATION FEES					4,698.01
c BOOKS/TAPES/PERIODICAL					3,818.92
d VITAMIN/MINERAL/FOOD					754,461.84
e OTHER RECEIPTS					337,807.74
f Medicare/Medicaid payments					
g Fees and contracts from government agencies					
94 Membership dues and assessments					
95 Interest on savings and temporary cash investments			14	92,032.20	
96 Dividends and interest from securities			14	12,148.72	
97 Net rental income or (loss) from real estate					
a debt-financed property					
b not debt-financed property					
98 Net rental income or (loss) from personal property					
99 Other investment income					
100 Gain or (loss) from sales of assets other than inventory					
101 Net income or (loss) from special events					
102 Gross profit or (loss) from sales of inventory					
103 Other revenue					
a					
b					
c					
d					
e					
104 Subtotal (add columns (B), (D), and (E))		0.00		104,180.92	2,580,693.58
105 Total (add line 104, columns (B), (D), and (E))					2,684,874.50

Note Line 105 plus line 1d, Part I, should equal the amount on line 12, Part I

Part VIII Relationship of Activities to the Accomplishment of Exempt Purposes (See page 32 of the instructions)

Line No	Explain how each activity for which income is reported in column (E) of Part VII contributed importantly to the accomplishment of the organization's exempt purposes (other than by providing funds for such purposes)
▼	SEE STATEMENT 6

Part IX Information Regarding Taxable Subsidiaries and Disregarded Entities (See page 32 of the instructions)

(A) Name, address, and EIN of corporation partnership, or disregarded entity	(B) Percentage of ownership interest	(C) Nature of activities	(D) Total income	(E) End-of-year assets
N/A	%			
	%			
	%			

Part X Information Regarding Transfers Associated with

(a) Did the organization, during the year, receive any funds, directly or indirectly, to...
(b) Did the organization, during the year, pay premiums, directly or indirectly, on a...
Note If "Yes" to (b), file Form 8870 and Form 4720 (see instructions)

Please Sign Here: Under penalties of perjury I declare that I have examined this return, including accompanying schedules and statements, and to the best of my knowledge and belief, it is true, correct, and complete. Declaration of preparer (other than officer) is based on all information furnished to him.

Signature of officer: *[Signature]* Date: 5/11

Preparer's signature: *William C. Riffel*

Firm's name (or yours if self-employed), address, and ZIP + 4: HANEY, RIFFEL, GALBRAITH
245 N. WACO, SUITE 410
WICHITA, KS 67202

SCHEDULE A
(Form 990 or 990-EZ)

Department of the Treasury
Internal Revenue Service

Organization Exempt Under Section 501(c)(3)

(Except Private Foundation) and Section 501(e), 501(f), 501(k),
501(n), or Section 4947(a)(1) Nonexempt Charitable Trust

Supplementary Information-(See separate instructions.)
▶ **MUST be completed by the above organizations and attached to their Form 990 or 990-EZ**

OMB No 1545-0047

2002

Name of the organization **THE CENTER FOR THE IMPROVEMENT OF HUMAN FUNCTIONING INTERNATIONAL, INC.** Employer identification number **48 0840415**

Part I Compensation of the Five Highest Paid Employees Other Than Officers, Directors, and Trustees
(See page 1 of the instructions List each one If there are none, enter "None")

(a) Name and address of each employee paid more than \$50,000	(b) Title and average hours per week devoted to position	(c) Compensation	(d) Contributions to employee benefit plans & deferred compensation	(e) Expense account and other allowances
LAURA L. BENSON ----- 4619 WEST 11TH, WICHITA, KS 67212	ADMINISTRATOR 50 HRS/WK	78,862.08	6,138.84	
RONALD E. HUNNINGHAKE, M.D. ----- 7318 GREENBRIAR CIRCLE, WICHITA, KS	MED. DOCTOR 50 HRS/WK	129,217.46	15,783.08	
XIAO LONG MENG ----- 3936 N. RUSHWOOD, WICHITA, KS 67226	ASSOC. DIRECTOR BIOCOMM. RESEARCH INST. 50 HRS/WK	62,727.13	8,143.44	
DEAN A. DODSON ----- 11497 SW 230TH ST, DOUGLASS, KS 67039	ASSIST. ADMIN. PHYSICAL PLANT/ MAINTENANCE 50 HRS/WK	58,861.82	1,138.84	
NINA MIKIROVA ----- 1004 SOUTH DALTON, WICHITA, KS 67207	SENIOR RESEARCH SCIENTIST 50 HRS/WK	52,741.60	0.00	
Total number of other employees paid over \$50,000 ▶	4			

Part II Compensation of the Five Highest Paid Independent Contractors for Professional Services
(See page 2 of the instructions List each one (whether individuals or firms) If there are none, enter "None")

(a) Name and address of each independent contractor paid more than \$50,000	(b) Type of service	(c) Compensation
NONE ----- ----- ----- ----- ----- ----- ----- ----- ----- ----- -----		
Total number of others receiving over \$50,000 for professional services ▶	0	

Part III Statements About Activities (See page 2 of the instructions)

	Yes	No
1 During the year, has the organization attempted to influence national, state, or local legislation, including any attempt to influence public opinion on a legislative matter or referendum? If "Yes," enter the total expenses paid or incurred in connection with the lobbying activities ▶ \$ _____ \$ _____ (Must equal amounts on line 38, Part VI-A, or line 1 of Part VI-B) Organizations that made an election under section 501(h) by filing Form 5768 must complete Part VI-A. Other organizations checking "Yes," must complete Part VI-B AND attach a statement giving a detailed description of the lobbying activities.		X
2 During the year, has the organization, either directly or indirectly, engaged in any of the following acts with any substantial contributors, trustees, directors, officers, creators, key employees, or members of their families, or with any taxable organization with which any such person is affiliated as an officer, director, trustee, majority owner, or principal beneficiary? (If the answer to any question is "Yes," attach a detailed statement explaining the transactions) SEE STATEMENT 7		
a Sale, exchange, or leasing of property?		X
b Lending of money or other extension of credit?		X
c Furnishing of goods, services, or facilities?		X
d Payment of compensation (or payment or reimbursement of expenses if more than \$1,000)?	X	
e Transfer of any part of its income or assets?		X
3 Does the organization make grants for scholarships, fellowships, student loans, etc.? (See Note below)		X
4 Do you have a section 403(b) annuity plan for your employees?	X	
Note Attach a statement to explain how the organization determines that individuals or organizations receiving grants or loans from it in furtherance of its charitable programs "qualify" to receive payments		

Part IV Reason for Non-Private Foundation Status (See pages 3 through 5 of the instructions)

The organization is not a private foundation because it is (Please check only ONE applicable box)

5 <input type="checkbox"/>	A church, convention of churches, or association of churches Section 170(b)(1)(A)(i)
6 <input type="checkbox"/>	A school Section 170(b)(1)(A)(ii) (Also complete Part V)
7 <input type="checkbox"/>	A hospital or a cooperative hospital service organization Section 170(b)(1)(A)(iii)
8 <input type="checkbox"/>	A Federal, state, or local government or governmental unit Section 170(b)(1)(A)(v)
9 <input checked="" type="checkbox"/>	A medical research organization operated in conjunction with a hospital Section 170(b)(1)(A)(iii) Enter the hospital's name, city, and state ▶ UNIVERSITY OF KANSAS MEDICAL CENTER, KANSAS CITY, MO UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE, SAN JUAN, PUERTO RICO
10 <input type="checkbox"/>	An organization operated for the benefit of a college or university owned or operated by a governmental unit Section 170(b)(1)(A)(iv) (Also complete the Support Schedule in Part IV-A)
11a <input type="checkbox"/>	An organization that normally receives a substantial part of its support from a governmental unit or from the general public Section 170(b)(1)(A)(vi) (Also complete the Support Schedule in Part IV-A)
11b <input type="checkbox"/>	A community trust Section 170(b)(1)(A)(vi) (Also complete the Support Schedule in Part IV-A)
12 <input type="checkbox"/>	An organization that normally receives (1) more than 33 1/3% of its support from contributions, membership fees, and gross receipts from activities related to its charitable, etc., functions - subject to certain exceptions, and (2) no more than 33 1/3% of its support from gross investment income and unrelated business taxable income (less section 511 tax) from businesses acquired by the organization after June 30, 1975 See section 509(a)(2) (Also complete the Support Schedule in Part IV-A)
13 <input type="checkbox"/>	An organization that is not controlled by any disqualified persons (other than foundation managers) and supports organizations described in (1) lines 5 through 12 above, or (2) section 501(c)(4), (5), or (6), if they meet the test of section 509(a)(2) (See section 509(a)(3))

Provide the following information about the supported organizations (See page 5 of the instructions)

(a) Name(s) of supported organization(s)	(b) Line number from above

14 An organization organized and operated to test for public safety Section 509(a)(4) (See page 5 of the instructions)

THE CENTER FOR THE IMPROVEMENT OF HUMAN

Schedule A (Form 990 or 990-EZ) 2002 **FUNCTIONING INTERNATIONAL, INC.**

48-0840415 Page 3

Part IV-A Support Schedule (Complete only if you checked a box on line 10, 11, or 12) Use cash method of accounting. **N/A**
 Note: You may use the worksheet in the instructions for converting from the accrual to the cash method of accounting.

Calendar year (or fiscal year beginning in)	(a) 2001	(b) 2000	(c) 1999	(d) 1998	(e) Total
15 Gifts, grants, and contributions received (Do not include unusual grants. See line 28.)					
16 Membership fees received					
17 Gross receipts from admissions, merchandise sold or services performed, or furnishing of facilities in any activity that is related to the organization's charitable, etc., purpose					
18 Gross income from interest, dividends, amounts received from payments on securities loans (section 512(a)(5)), rents, royalties, and unrelated business taxable income (less section 511 taxes) from businesses acquired by the organization after June 30, 1975					
19 Net income from unrelated business activities not included in line 18					
20 Tax revenues levied for the organization's benefit and either paid to it or expended on its behalf					
21 The value of services or facilities furnished to the organization by a governmental unit without charge. Do not include the value of services or facilities generally furnished to the public without charge.					
22 Other income. Attach a schedule. Do not include gain or (loss) from sale of capital assets.					
23 Total of lines 15 through 22	0.00	0.00	0.00	0.00	0.00
24 Line 23 minus line 17					
25 Enter 1% of line 23					

26 Organizations described on lines 10 or 11	a Enter 2% of amount in column (e), line 24	26a	N/A
b Prepare a list for your records to show the name of and amount contributed by each person (other than a governmental unit or publicly supported organization) whose total gifts for 1998 through 2001 exceeded the amount shown in line 26a. Do not file this list with your return. Enter the sum of all these excess amounts.		26b	N/A
c Total support for section 509(a)(1) test. Enter line 24, column (e).		26c	N/A
d Add Amounts from column (e) for lines 18 _____ 19 _____		26d	N/A
	22 _____ 26b _____	26e	N/A
e Public support (line 26c minus line 26d total)		26f	N/A %
f Public support percentage (line 26e (numerator) divided by line 26c (denominator))			

27 Organizations described on line 12 a For amounts included in lines 15, 16, and 17 that were received from a "disqualified person," prepare a list for your records to show the name of, and total amounts received in each year from, each "disqualified person." Do not file this list with your return. Enter the sum of such amounts for each year.

	(2001)	(2000)	(1999)	(1998)	
b For any amount included in line 17 that was received from each person (other than "disqualified persons"), prepare a list for your records to show the name of, and amount received for each year that was more than the larger of (1) the amount on line 25 for the year or (2) \$5,000 (Include in the list organizations described in lines 5 through 11, as well as individuals.) Do not file this list with your return. After computing the difference between the amount received and the larger amount described in (1) or (2), enter the sum of these differences (the excess amounts) for each year.					
c Add Amounts from column (e) for lines 15 _____ 16 _____					
	17 _____ 20 _____				
d Add Line 27a total _____ and line 27b total _____					
e Public support (line 27c total minus line 27d total)					27e
f Total support for section 509(a)(2) test. Enter amount on line 23, column (e).					27f
g Public support percentage (line 27e (numerator) divided by line 27f (denominator))					27g
h Investment income percentage (line 18, column (e) (numerator) divided by line 27f (denominator))					27h

28 Unusual Grants For an organization described in line 10, 11, or 12 that received any unusual grants during 1998 through 2001, prepare a list for your records to show, for each year, the name of the contributor, the date and amount of the grant, and a brief description of the nature of the grant. Do not file this list with your return. Do not include these grants in line 15.

Part V Private School Questionnaire (See page 7 of the instructions)

N/A

(To be completed ONLY by schools that checked the box on line 6 in Part IV)

	Yes	No
29 Does the organization have a racially nondiscriminatory policy toward students by statement in its charter, bylaws, other governing instrument, or in a resolution of its governing body?		
30 Does the organization include a statement of its racially nondiscriminatory policy toward students in all its brochures, catalogues, and other written communications with the public dealing with student admissions, programs, and scholarships?		
31 Has the organization publicized its racially nondiscriminatory policy through newspaper or broadcast media during the period of solicitation for students, or during the registration period if it has no solicitation program, in a way that makes the policy known to all parts of the general community it serves? If "Yes," please describe, if "No," please explain (If you need more space, attach a separate statement)		
<hr/> <hr/> <hr/>		
32 Does the organization maintain the following		
a Records indicating the racial composition of the student body, faculty, and administrative staff?		
b Records documenting that scholarships and other financial assistance are awarded on a racially nondiscriminatory basis?		
c Copies of all catalogues, brochures, announcements, and other written communications to the public dealing with student admissions, programs, and scholarships?		
d Copies of all material used by the organization or on its behalf to solicit contributions? If you answered "No" to any of the above, please explain (If you need more space, attach a separate statement)		
<hr/> <hr/>		
33 Does the organization discriminate by race in any way with respect to		
a Students' rights or privileges?		
b Admissions policies?		
c Employment of faculty or administrative staff?		
d Scholarships or other financial assistance?		
e Educational policies?		
f Use of facilities?		
g Athletic programs?		
h Other extracurricular activities? If you answered "Yes" to any of the above, please explain (If you need more space, attach a separate statement)		
<hr/> <hr/>		
34 a Does the organization receive any financial aid or assistance from a governmental agency?		
b Has the organization's right to such aid ever been revoked or suspended? If you answered "Yes" to either 34a or b, please explain using an attached statement		
35 Does the organization certify that it has complied with the applicable requirements of sections 4 01 through 4 05 of Rev Proc 75-50, 1975-2 C B 587, covering racial nondiscrimination? If "No," attach an explanation		

Part VI-A Lobbying Expenditures by Electing Public Charities (See page 9 of the instructions)

N/A

(To be completed ONLY by an eligible organization that filed Form 5768)

Check a if the organization belongs to an affiliated group Check b if you checked "a" and "limited control" provisions apply

Limits on Lobbying Expenditures

(The term "expenditures" means amounts paid or incurred)

	(a) Affiliated group totals	(b) To be completed for ALL electing organizations
	N/A	
36 Total lobbying expenditures to influence public opinion (grassroots lobbying)	36	
37 Total lobbying expenditures to influence a legislative body (direct lobbying)	37	
38 Total lobbying expenditures (add lines 36 and 37)	38	
39 Other exempt purpose expenditures	39	
40 Total exempt purpose expenditures (add lines 38 and 39)	40	
41 Lobbying nontaxable amount Enter the amount from the following table -		
If the amount on line 40 is -		
Not over \$500,000	20% of the amount on line 40	
Over \$500,000 but not over \$1,000,000	\$100,000 plus 15% of the excess over \$500,000	
Over \$1,000,000 but not over \$1,500,000	\$175,000 plus 10% of the excess over \$1,000,000	
Over \$1,500,000 but not over \$17,000,000	\$225,000 plus 5% of the excess over \$1,500,000	
Over \$17,000,000	\$1,000,000	
42 Grassroots nontaxable amount (enter 25% of line 41)	42	
43 Subtract line 42 from line 36 Enter -0- if line 42 is more than line 36	43	
44 Subtract line 41 from line 38 Enter -0- if line 41 is more than line 38	44	

Caution If there is an amount on either line 43 or line 44, you must file Form 4720

4-Year Averaging Period Under Section 501(h)

(Some organizations that made a section 501(h) election do not have to complete all of the five columns below See the instructions for lines 45 through 50 on page 11 of the instructions)

Calendar year (or fiscal year beginning in)	Lobbying Expenditures During 4-Year Averaging Period				N/A (e) Total
	(a) 2002	(b) 2001	(c) 2000	(d) 1999	
45 Lobbying nontaxable amount					0.00
46 Lobbying ceiling amount (150% of line 45(e))					0.00
47 Total lobbying expenditures					0.00
48 Grassroots nontaxable amount					0.00
49 Grassroots ceiling amount (150% of line 48(e))					0.00
50 Grassroots lobbying expenditures					0.00

Part VI-B Lobbying Activity by Nonelecting Public Charities

(For reporting only by organizations that did not complete Part VI-A) (See page 11 of the instructions)

N/A

During the year, did the organization attempt to influence national, state or local legislation, including any attempt to influence public opinion on a legislative matter or referendum through the use of

- a Volunteers
- b Paid staff or management (Include compensation in expenses reported on lines c through h)
- c Media advertisements
- d Mailings to members, legislators, or the public
- e Publications, or published or broadcast statements
- f Grants to other organizations for lobbying purposes
- g Direct contact with legislators, their staffs, government officials, or a legislative body
- h Rallies, demonstrations, seminars, conventions, speeches, lectures, or any other means
- i Total lobbying expenditures (Add lines c through h)

Yes	No	Amount
		0.00

If "Yes" to any of the above, also attach a statement giving a detailed description of the lobbying activities

FORM 990	OTHER CHANGES IN NET ASSETS OR FUND BALANCES	STATEMENT	1
----------	--	-----------	---

DESCRIPTION	AMOUNT
ADJUSTMENT TO UNREALIZED GAIN(LOSS) ON WRITE-DOWN OF VALUE OF MARKETABLE SECS. AND OTHER INVESTMENTS	<252,497.46>
TOTAL TO FORM 990, PART I, LINE 20	<252,497.46>

FORM 990	OTHER EXPENSES	STATEMENT	2
----------	----------------	-----------	---

DESCRIPTION	(A) TOTAL	(B) PROGRAM SERVICES	(C) MANAGEMENT AND GENERAL	(D) FUNDRAISING
CONSULTANT FEES	261,924.01	255,338.09	0.00	6,585.92
CONTRACT LABOR	47,749.23	25,945.45	21,098.23	705.55
MALPRACTICE				
INSURANCE	20,378.25	20,378.25	0.00	0.00
STAFF DEVELOPMENT	14,294.27	11,642.15	2,219.62	432.50
TAXES	303.70	0.00	303.70	0.00
INSURANCE -				
OCCUPANCY	18,532.00	17,426.21	921.47	184.32
OUTSIDE LAB TESTING	41,912.56	41,912.56	0.00	0.00
OUTSIDE SERVICES	34,457.35	15,578.19	18,218.94	660.22
SALES TAX	11,394.10	11,394.10	0.00	0.00
BANK SERVICE CHARGES	43,789.16	43,594.12	195.04	0.00
STAFF RECOGNITION	16,059.61	10,969.53	4,915.40	174.68
ADVERTISING	139,013.08	127,288.09	2,520.02	9,204.97
VEHICLE EXPENSE	695.02	34.23	660.79	0.00
TRAVEL	37,739.12	33,853.91	3,809.31	75.90
SUBSCRIPTIONS	6,325.74	5,995.61	305.16	24.97
DUES	13,184.96	11,328.96	1,425.00	431.00
PROFESSIONAL				
SERVICES	49,281.11	37,956.61	11,324.50	0.00
GUEST EXPENSE	309.18	0.00	0.00	309.18
MISCELLANEOUS				
EXPENSE	626.51	0.00	626.51	0.00
INSURANCE - LABOR	7,867.00	7,394.98	393.35	78.67
OFF-SITE RESEARCH	20,000.00	20,000.00	0.00	0.00
TRANSFER TO DR. HUGH				
RIORDAN FOUNDATION	55,002.00	55,002.00	0.00	0.00
TOTAL TO FM 990, LN 43	840,837.96	753,033.04	68,937.04	18,867.88

FORM 990 OTHER INVESTMENTS STATEMENT 3

DESCRIPTION	VALUATION METHOD	AMOUNT
MRKT EQTY STOCK, MUTUAL FUNDS & INVESTMENT PRTNRSH	MARKET VALUE	1,340,126.76
TOTAL TO FORM 990, PART IV, LINE 56, COLUMN B		1,340,126.76

FORM 990 OTHER ASSETS STATEMENT 4

DESCRIPTION	AMOUNT	
PREPAID POSTAGE	3,107.94	
DEPOSITS	45.00	
PREPAID INSURANCE	486.59	
TOTAL TO FORM 990, PART IV, LINE 58, COLUMN B		3,639.53

FORM 990 OTHER REVENUE NOT INCLUDED ON FORM 990 STATEMENT 5

DESCRIPTION	AMOUNT	
TRANSFERS	55,002.00	
NET UNREALIZED GAIN (LOSS) ON INVESTMENTS	<252,497.46>	
TOTAL TO FORM 990, PART IV-A		<197,495.46>

FORM 990 PART VIII - RELATIONSHIP OF ACTIVITIES TO ACCOMPLISHMENT OF EXEMPT PURPOSES STATEMENT 6

LINE	EXPLANATION OF RELATIONSHIP OF ACTIVITIES
93A	FEES FOR MEDICAL SERVICES-RELATED TO OUR EXEMPT PURPOSE OF PROVIDING MEDICAL TREATMENT FOR RESEARCH.
93B	FEES FROM SEMINARS AND WORKSHOPS-RELATES TO OUR ACTIVITY OF PROVIDING NEW DIRECTIONS FOR RESEARCH AND MEDICAL TREATMENT TO THE HEALTH RELATED PROFESSIONS.
93C	EDUCATIONAL ITEMS-RELATED TO OUR PURPOSE OF INFORMING PEOPLE OF MEDICAL ISSUES.
93D	RELATED TO OUR EXEMPT PURPOSE OF PROVIDING ITEMS THAT WILL AFFECT PEOPLE'S HEALTH THROUGH OUR MEDICAL RESEARCH TO MAKE PEOPLE MORE NUTRIENT AND HEALTH CONSCIOUS.

THE CENTER FOR THE IMPROVEMENT OF
HUMAN FUNCTIONING INTERNATIONAL, INC
DECEMBER 31, 2002

48-0840415

SCHEDULE 1

Program Services Rendered – Form 990, Part III, Line (a)

The Center is a complex medical, research, educational organization with four major divisions

Olive W Garvey Center for Healing Arts
Bio-Center Laboratory
Bio-Medical Synergistics Education Institute
Bio-Communications Research Institute

The Olive W Garvey Center for Healing Arts exists to evaluate and treat people who have not responded well to standard medical care. To benefit from The Center's in-depth evaluation and treatment recommendations, people have come to The Center from all 50 states, The District of Columbia and 40 foreign countries.

As a driving force for a new emphasis in medicine, The Center is growing in its services and capability. These services include laboratory tests which are of an experimental and research nature that are not generally available and include various blood and plasma tests, complete amino acid tests, and human hair tests. The emphasis of these various tests is upon research related to nutrition and the effect of environmental factors upon human functioning. More and more patients are demanding this type of care based upon nutritional medicine and each individual's unique biochemistry. The Center's physicians with 100 years of medical experience in diverse specialties work together with all members of the treatment team to provide coordinated care – the cornerstone of The Center's effectiveness.

The Bio-Center Laboratory exists to provide diagnostic services for physicians and hospitals throughout the country to help reveal and monitor the correction of a variety of biochemical impairments.

Using advanced instrumentation including computerized atomic absorption and plasma spectrometry, gas chromatography, high-pressure liquid chromatography, spectrophotometry, spectrofluorometry and gamma counter analyzers, The Laboratory provides a resource for complex test procedures. All assays are performed by highly skilled technologists and technicians using precision quality control techniques to ensure their accuracy. The Bio-Center Laboratory has received continuous certification from state and federal agencies since 1976.

The Bio-Medical Synergistics Education Institute exists to provide learning opportunities for physicians, nurses, psychologists and allied health personnel directly involved in health care or research. In addition to sponsoring short courses, conferences and seminars, The Institute publishes books, The Health Hunter Newsletter and operates the Mabee Library which serves as a reference resource for researchers, students, staff and the public who become library associates.

The Bio-Communications Research Institute – (see attached)

YEAR 2002 RESEARCH → YEAR END REPORT

INTRODUCTION

Early last year, the Biocommunications Research Institute provided the board of directors with a list of its goals for years 2002 and 2003. The purpose of the present document is to provide a year-end summary of our progress toward meeting these goals. Overall, 2002 was a productive year for our Research Institute, with substantial progress being made in each of our four major research areas:

- Vitamin C Therapy

We continue to be at the forefront of research concerning the use of intravenous ascorbate to promote health and treat cancer. This past year, we submitted manuscripts detailing some of our clinical and laboratory data, including the National Cancer Institute's analysis of the Center's most successful cases treating cancer intravenous ascorbate. We have also collaborated with scientists at the University of Puerto Rico School of Medicine to begin clinical and laboratory ascorbate research there.

- Nutrition

We made progress in examining the potential health benefits of lipoic acid, including a successful case study with a hepatitis patient. We also embarked on a five-year program sponsored by "Trees of Life" to examine nutrients contained in the Moringa Tree. We have already produced extracts from this plant that inhibit tumor growth in animal models. Moreover, we have begun exciting research into the effects of nutrition on rat growth and development. We are able to show that deprivation of even a single nutrient significantly compromises rat growth and alters rat behavior. We hope to expand on these studies in the coming year.

- Therapeutics

Our studies into the use of herbal and orthomolecular treatments for cancer and other illnesses yielded promising results in 2002. We started a research program aimed at identifying plant extracts and food antigens that can affect biological responses to cancer. This effort has already led to the development of new plant extracts that inhibit tumor growth in animal models. We also are collaborating with Dr. Jeanne Drisko at the Kansas University School of Medicine in two clinical trials: one testing the benefits of probiotics and diet modification in patients with irritable bowel syndrome, and another examining the effects of plant and bacterial extracts developed during our RECNAAC project on ovarian cancer.

YEAR 2002 RESEARCH → YEAR END REPORT

- **Diagnosis**

Our efforts to develop new diagnostic tools for physicians are progressing quite well. We have developed fluorescence-based techniques to analyze blood serum and white blood cells. Manuscripts describing these methods are in preparation. We hope these methods will eventually provide insight into the overall 'energy status' of white blood cells. We also made considerable progress in developing a spreadsheet-based program for entry, display, and analysis of patient history and lab test data.

A point-by-point analysis of our progress toward each stated research goal is provided below. The purpose and background for each goal, as originally submitted to the Center's Board of Directors, is given in plain text. The Institute's progress toward meeting each goal is given in green type. The symbols placed next to each goal statement (see accompanying key) indicate the extent to which each goal was met (note that these were two-year goals). In some

Key	
☺	Completed: positive results
☹	Completed: negative results
⚙	Significant Progress Made
▷	Work Under Way
■	Abandoned or On Hold

cases, information concerning our plans for the coming year is also provided. A full description of our 2003 research goals, however, will be provided in another document.

YEAR 2002 RESEARCH → YEAR END REPORT

VITAMIN C THERAPY

Clinical Trials

Encouraging clinical studies of intravenous ascorbate at other sites is a high priority for us. To this end, we have been collaborating with Dr. Michael Gonzales and his "RECNAC II" research team at the University of Puerto Rico. RECNAC II is planning to submit two proposals for clinical trials in Puerto Rico, both of which we will help fund if approved.

- A Phase II/III study comparing sodium ascorbate therapy to controls in cancer patients. The study may focus on breast cancer or lymphoma, but other cancers will be considered.
- A comparison of ascorbate pharmacokinetics in cancer patients to that in healthy adults. The idea for this study comes from preliminary RECNAC data suggesting that cancer patients "soak up" more vitamin C than healthy adults, and thus need higher doses to reach a given plasma ascorbate level.

Dr. Chan Park, who has a long-term interest in the effects of vitamin C on leukemia cells, joined our research team last year. He is also examining avenues for clinical trials, including

- Multi-center phase II/III studies examining the efficacy of intravenous ascorbate, alone or with other modalities, in treating leukemia patients.
- A clinical trial at the Center where our scientists could obtain blood samples from co-learners with leukemia and then measure the dose-response of their leukemia cells to sodium ascorbate. By comparing these results with the actual benefits the co-learners derive from ascorbate therapy, we may develop a 'screening' method to predict the outcome of ascorbate therapy in individual leukemia patients.

Goal 1) *To have at least two phase II or III clinical trials using intravenous vitamin C, alone or with other nutrients, in progress by the end of 2003.*

▷ Work Under Way

Dr. Michael Gonzalez has been working to get his RECNAC II research laboratory up and running this year. He has received permission to conduct clinical trials with intravenous ascorbate, and has already obtained some pharmacokinetics data. We expect the RECNAC II project to have pharmacokinetic studies and a phase II/III clinical trial with intravenous

YEAR 2002 RESEARCH → YEAR END REPORT

vitamin C under way by the end of next year. We plan to continue our collaboration with Dr. Gonzalez and the RECNAAC II research team.

In 2002, Dr. Chan Park sought collaborators for a phase II or III clinical trial with intravenous ascorbate. He has been in contact with three sites, but thus far has not been able to set up a phase II/III clinical trial. He has thus far obtained bone marrow samples from a single patient. We will be reducing Dr. Park's involvement in 2003, as results have not been commensurate with funding. We will pursue collaborations with other scientists, including a Korea doctor who successfully treated a cancer patient with intravenous vitamin C.

We had hoped to conduct a trial to examine the effect of intravenous ascorbate on the immune system, and indeed obtained expedited IRB approval for it, in 2001. However, this project is on hold until other priorities are addressed or additional personnel are made available. In an effort to overcome the work force limitations that have stalled this project thus far, we are looking into the possibility of paying an outside laboratory, such as Immunosciences Lab, to run immune tests such as the natural killer cell activity assay for us. We would also like to someday correlate serum and urine ascorbate levels with immune cell function in adults from the general population.

Goal 2) *To conduct a clinical study examining the effects of intravenous vitamin C on immune cells in cancer and chronic fatigue patients. We hope to commence this study by the end of 2003.*

Goal 3) *To conduct a clinical study examining the correlation between immune cell functioning and plasma ascorbate concentrations. We hope to commence this study by the end of 2003.*

■ **On Hold**

A lack of sufficient personnel in light of current priorities has prevented us from starting these studies. We still intend to carry out this work, but not until after goals (12) through (15) below have been successfully achieved.

In the meanwhile, submitted a write-up of our older data on supplementation and the immune system (obtained in staff volunteers) to the *Journal of Orthomolecular Medicine* in 2002. We are still waiting for the reviewers' comments and the decision of the journal editor.

YEAR 2002 RESEARCH → YEAR END REPORT

Laboratory Studies

We will assist in funding collaborative efforts to continue laboratory research into the biological effects of vitamin C on cancer and normal cells. Dr. Park's colleagues in Korea are working to study the molecular mechanisms of ascorbate toxicity toward leukemia cells. In the meantime, Dr. Gonzales and his RECNAAC II team have ambitious plans regarding vitamin C research. They hope to examine its effects under hyperbaric (high oxygen) or hypoxic (low oxygen) conditions, alone or with other nutrients such as copper, lipoic acid, coenzyme Q10, acetyl-carnitine, and omega-3 fatty acids. Moreover, RECNAAC II hopes to measure mitochondria membrane potentials in normal and cancerous cells to see if this property is associated with differentiation or cell growth. The effect of ascorbate on mitochondrial potential and function will also be assessed.

Goal 4) *To collaborate with other laboratories in experiments designed to further explore the biological effects of ascorbate in cancer.*

▷ Work Under Way

Dr. Michael Gonzalez has been working to get his RECNAAC II research laboratory up and running this year. He has hired a research scientist for his laboratory and is setting up experimental protocols. Meanwhile, Dr. Nina Mikirova of the Biocommunications Research Institute has been developing assays for mitochondrial activity that may be useful in assessing the effect of vitamin C on cell metabolism and oxidation-reduction status. We plan to assist Dr. Gonzalez in funding his research, and hope that his interests in mitochondrial function as it may relate to transformation and tumor growth can be combined with Dr. Mikirova's efforts to develop mitochondria assays and assess cell energy status.

Dr. Chan Park has secured funding for his laboratory at the Samsung Medical Center in Seoul, Korea. He is hoping to examine the ability of sodium ascorbate, at sufficient doses, to induce programmed cell death (apoptosis) in leukemia cells.

Publications

The following manuscripts, or potential manuscripts, are under consideration

- A description of how vitamin C supplementation affects immune cell performance (recently submitted to the Journal of Orthomolecular Medicine)

YEAR 2002 RESEARCH → YEAR END REPORT

- The results of our Phase I clinical study in Omaha, Nebraska, with intravenous vitamin C and terminal cancer patients (currently being revised by a co-author outside the institute)
- Details concerning the verification of pathology reports in case studies of Center co-learners treated with intravenous vitamin C (currently being revised by co-authors at the NIH)
- The results of our experiments in guinea pig demonstrating an inverse correlation between intra-tumor ascorbate concentrations and tumor growth rates (in preparation)
- A review article concerning intravenous vitamin C and cancer (in preparation by Dr. Gonzalez)
- A review of the Center's experience with ascorbate therapy, including dosage data from all patients who have been treated there (under consideration)

Goal 5) *To publish four papers in the next two years detailing the Center's experience with intravenous vitamin C and cancer.*

⚙ Significant Progress Made

The following manuscripts on vitamin C were submitted to peer-review journals in 2002:

- An article by Dr. Joseph Casciari describing the effects of oral vitamin C supplementation on immune cell functioning in healthy volunteers.
- An article by Drs. Mark Levine and Sebastian Padayatty from the National Cancer Institute describing, among other things, a couple of the Center's most striking case studies of intravenous vitamin C treatments for cancer.
- An article by Dr. Michael Gonzales concerning the effects of high dose vitamin C on DNA damage.
- An article by Dr. Nina Mikirova concerning the combined effects of vitamin C and electromagnetic fields on cancer cell growth.

Preparation of the following vitamin C manuscripts began in 2002:

- An article by Dr. Joseph Casciari describing the effects of vitamin C on tumor growth in guinea pigs, focusing on the inverse correlation between intra-tumor vitamin C levels and tumor growth rates.
- A comprehensive review of intravenous vitamin C therapy by Dr. Michael Gonzales.

YEAR 2002 RESEARCH → YEAR END REPORT

In addition to the articles described above, we would like to publish more of the Center's best case studies with intravenous vitamin C. The National Cancer Institute's Office of Cancer Complementary and Alternative Medicine has expressed interest in having our cases published.

Also, we are still trying to get the results of our Phase I intravenous ascorbate trial published. Dr. Casciari completed the article in the fall of 2001, but our co-author (Dr. Margaret Tempero, who supervised the trial at the Eppley Institute for Research in Cancer and Applied Diseases in Omaha, Nebraska) has not completed her review of it. At this time we are planning to submit the article with or without her approval in 2003.

YEAR 2002 RESEARCH → YEAR END REPORT

NUTRITION

The Moringa Tree

We plan to form a five-year partnership with Trees for Life to examine the nutritional content and medicinal value of leaves from the tree *Moringa Oleifera*. Our hypothesis is that the Moringa leaves are rich in vitamin A and may be helpful for vitamin A deficiency problems, including blindness. We hope to analyze the nutrient content of these leaves, particularly vitamin A, amino acid, fatty acid, and mineral levels. We will also incorporate Moringa leaf extract in our antigen screening study (below). Trees of Life will test the effect of these leaves on school children in Allahabad, India. These students often suffer from anemia, skin diseases, and parasites.

Goal 6) *To determine the compositions of key nutrients in extracts from the leaves of the Moringa tree by the end of 2003*

Goal 7) *To assess the therapeutic potential of nutrients from the Moringa tree. We hope to have clinical studies in progress by the end of 2003.*

 Significant Progress

In 2002, we produced water-soluble extracts of Moringa tree leaves or seeds. After processing, we found that the Moringa leaf extract had capillary electrophoresis profiles similar to those of plant extracts that inhibit tumor growth in vivo. We tested this Moringa leaf extract in an animal tumor model, and found that it inhibited tumor growth by roughly seventy percent. We suspect, however, that some of the key ingredients in Moringa leaves may not be water-soluble. Therefore, we will examine other methods for extracting ingredients from these leaves.

Lipoic Acid

We have been collaborating with Dr. Gary Branum of Wichita State University on lipoic acid measurements, and have largely established our procedures for measuring lipoic acid levels in blood and urine. As Dr. Branum will not be available for the rest of the year, we hope to resume this work in 2003.

Goal 8) *To begin assessing lipoic acid pharmacokinetics and metabolism in humans by the end of 2003.*

▷ Work Under Way

YEAR 2002 RESEARCH → YEAR END REPORT

While waiting for Dr. Barnum to resume his work in 2003, we provided research funding for an individual with Hepatitis C to obtain treatment using intravenous vitamin C and lipoic acid. The results were positive. We hope to do more clinical testing with lipoic acid, and to resume our pharmacokinetics and metabolism experiments, in 2003.

Organic Gardening

We are working to determine if organic gardening (using natural fertilizers in the absence of pesticides) confers a nutritional advantage to plants. Last year, we made substantial progress in evaluating nutritional contents of vegetables from our garden. This year we hope to focus on mineral content, fatty acids, amino acids, and lycopene of garden vegetables and compare them with produce obtained at the grocery store or other sources. We plan to maintain our certification for organic gardening and to increase the size of our garden by one-half acre. We will continue using it to obtain produce for the Taste of Health as well as to provide plant materials for cancer research projects.

Goal 9) *To complete measurements of nutrient content in vegetables grown in the Center's organic garden by the end of 2003.*

⚙ Significant Progress

We have analyzed mineral contents of several vegetables from the Center's organic garden, but the data have not yet been fully analyzed. We have also made progress in developing an assay for measuring fatty acid content in vegetables. This protocol will be tested in 2003.

Meanwhile, the organic garden continues to be a source of raw materials for our cancer research projects (see below). It also supplies vegetables and herbs for the Taste of Health.

Goal 10) *Maintain and expand the organic garden and to continue experiments designed to determine the effects of soil paramagnetism on plant growth.*

⚙ Significant Progress

Experiments with paramagnetism are completed, and consistent positive results were obtained. Dr. Melvin Epp summarized the data in a recent Lunch and Lecture presentation. A manuscript detailing these results is in preparation.

YEAR 2002 RESEARCH → YEAR END REPORT

Effect of Nutrients on Health

To learn how nutrition affects health in laboratory animals, we would like to conduct experiments that examine how the absence of any single essential nutrients will affect growth and health

Goal 11) *To design and conduct an experiment to observe and monitor rodents fed a complete diet with the exclusion of a single nutrient. We hope to achieve this by the end of 2003.*

☺ Completed: positive results

With the help of Dr. Cindy Feldkamp, a Kansas Veterinarian, we compared the growth, health, and behavior of rats fed a normal diet to those of rats fed a diet deficient in a single nutrient. The nutrients tested were thiamine, pantothenic acid, pyridoxine, and folic acid. Results were quite dramatic. For example, thiamine deprivation caused rats to lose their hair and stunted their growth to roughly one third (by mass) of normal.

This experiment was so successful that we are planning a series of new studies to expand upon our findings. We will examine how deprivation of other nutrients affects rats. We will also determine the effect of simultaneously depriving the rats of two or more nutrients. Finally, we will examine these effects in tumor bearing rats. We are planning to conduct this research in a new facility (currently under construction) starting in the summer of 2003.

YEAR 2002 RESEARCH → YEAR END REPORT

THERAPEUTICS

The Antigen Library Project

The antigen library project will be the major focus for our research staff during the year 2002. This project was motivated by the observation that plant extracts showing efficacy against tumors had biochemical profiles (as determined by capillary electrophoresis and high pressure liquid chromatography) similar to those of tumor cell lysates (extracts from dead tumor cells). We are now attempting to compile biochemical profiles of food antigens, plant extracts and tumor cell lysates and to identify key components of each. In addition, we will be testing these components for their ability to inhibit tumor cell growth, prevent tumor angiogenesis, and to enhance immune cell functioning. This project involves several distinct goals as part of its overall thrust.

Goal 12) *To complete biochemical analysis of (a) food antigens used in the BioCenter Laboratory's food sensitivity screen; (b) lysates from a variety of normal and cancerous cell; and (c) extracts from a variety of plants thought to have medicinal value. We hope to complete this by the end of 2002.*

☺ Completed: positive results

We have thus far obtained and analyzed extracts from over fifty plants, including sweet potatoes, tomatoes, asparagus, melons, gourds, beets, carrots, and garlic. In addition, we have analyzed lysates of eighteen cell lines, including over a dozen types of human tumor cells. Based on our analysis, a water-soluble extract from the laminaria plant appears to be particularly promising as an anti-cancer agent. Oral administration of this extract inhibits tumor growth in mice by roughly seventy-five percent; moreover, the extract is non-toxic at doses one hundred times higher than that shown to inhibit tumor growth.

We plan to expand upon this work in 2003. We will attempt to refine our biochemical analysis by digesting our extracts and attempting to identify the subsequent molecular fragments. We will also use statistical algorithms (below) to find plant extracts with compositions most similar to those of tumor cell extracts.

Goal 13) *To conduct a statistical analysis of the data obtained in Goal 12, with specific emphasis on clustering different substances into categories based on similar biochemical profiles and*

YEAR 2002 RESEARCH → YEAR END REPORT

finding substances with profiles similar to those of extracts known to inhibit tumor growth. We hope to complete this by the middle of 2003.

⚙ Significant Progress

We recently developed two statistical protocols for sorting biochemical data from plant and tumor cell extracts. The first employs a standard statistical technique called “clustering analysis” while the second scores extracts based on how they differ from specific tumor cell extracts. We plan to use these protocols in 2003 to identify plant extracts that most closely match tumor cell extracts.

Goal 14) *To conduct biological tests, including tumor growth inhibition measurements, immune cell function measurements, and angiogenesis inhibition studies, on the most promising ingredients identified in Goal 13. It is our hope to find a substance, or a combination of substances, that inhibits tumor growth by at least ninety percent in our standard mouse tumor-screening model. We hope to have this in progress by the end of 2003.*

⚙ Significant Progress

We have already begun tumor growth inhibition assays in animals (see above discussion of results with laminaria extracts). With the statistical methods described above, we will be able to identify more candidate extracts for growth inhibition studies.

Efforts are under way to measure the effect of plant extracts on the ability of white blood cells to kill tumor cells. We have come across a technical difficulty: our methods for measuring cell viability depend upon fluorescent markers, but the fluorescence generated by these markers seems to be affected by components in our plant extracts. We hope to find a solution to this problem in 2003.

We lacked the personnel to conduct angiogenesis inhibition studies. We will carry this work out in 2003 if time permits.

YEAR 2002 RESEARCH → YEAR END REPORT

Goal 15) *To complete, by the end of 2003, identification of key components in extracts from Convolvulus arvensis and Lactobacillus fermentum, two extracts that have shown efficacy against tumors in vivo.*

▷ Work Under Way

Our efforts in this regard have been thus far unsuccessful. While we are able to identify classes of molecules (such as polysaccharides and proteins), we are not yet able to discern structures or determine molecular masses of individual components. We have ruled out the use of mass spectroscopy for this purpose, as it does not appear to work for the higher molecular weight components that we are most interested in. In 2003, we will concentrate on improving our existing techniques (high pressure liquid chromatography, capillary electrophoresis) to gain more information on the high molecular mass proteins that we consider to be the active molecules in our extracts.

Clinical Studies → Orthomolecular / Holistic Treatments

We hope to help launch clinical trials to test therapeutic approaches developed at the Center by its physicians or by our research institute. We have developed a good relationship with Dr. Jeanne Drisko at the Kansas University School of Medicine, who is interested in holistic therapies. She has expressed a willingness to test extracts from *Convolvulus arvensis* and *Lactobacillus fermentum* in patients with refractory ovarian cancer. We will also provide her with funding for a clinical study using orthomolecular treatments (eliminating toxic foods, providing nutritional support and probiotics) for irritable bowel syndrome.

We would also like to set up, at the Center or elsewhere, a clinical trial using vitamin B₁₂ to treat multiple myeloma. The Institute will also be sponsoring master's level research into the art of therapeutic touch. We are hoping to use infrared imaging to monitor the effects of therapeutic touch, as well as auricular therapy, on circulation.

Goal 16) *To have at least two clinical studies using orthomolecular or complementary therapies in progress by the end of 2003.*

☺ Completed: positive results

YEAR 2002 RESEARCH → YEAR END REPORT

Our collaborations with Dr. Jeanne Drisko have been fruitful. Two clinical trials using alternative therapies are already under way:

- A clinical trial examining the effects of probiotics and diet modification on irritable bowel syndrome in adults who are refractory to standard medical care. Preliminary data based on seven patients demonstrate significant decreases in the severity of symptoms with treatment. Dr. Drisko is hoping to present these results at a large gastroenterology meeting this spring.
- A phase III clinical trial using extracts from *Convolvulus arvensis* and *Lactobacillus fermentum* (both developed by the Biocommunications Research Institute) in combination with liposomal doxorubicin to treat patients with refractory ovarian cancer.

These clinical trials will continue in 2003, and we will seek ways to expand our collaborations with Dr. Drisko.

We also conducted a clinical study into the effects of therapeutic touch. However, our results were inconclusive. We will not be continuing this work in 2003.

YEAR 2002 RESEARCH → YEAR END REPORT

DIAGNOSTICS

Infrared Imaging

Last year, the Center upgraded its infrared imaging equipment. Because of its ability to detect temperature gradients and changes, we believe that imaging of this sort can provide a sensitive measure of circulation. This will help us in assessing the physiological effects of therapeutic touch (see above). Moreover, it may provide an improved method for detecting breast cancer, since this disease is often accompanied by neo-vascularization and increased blood flow to the affected region. We thus hope to launch a five-year study to test infrared imaging as a screen for breast cancer.

Goal 17) *To begin, by the end of 2002, a five year clinical trial to study breast health, with the goal of determining if infrared imaging is predictive of breast cancer. Participating women will be imaged repeatedly over a five-year period, and the incidence of breast cancer will be noted.*

■ On Hold

We postponed this project when the manufacturer of our infrared equipment refused to support the instrument or maintain calibration of it during the study.

Lymphocyte Metabolism

The Clayton Research Institute at the University of Texas has been working for nearly two decades to develop methods that will enable doctors to determine patients' health and nutritional status by examining the metabolic capabilities of their lymphocytes. However, this research team, founded by Dr. William Shive, now deceased, and currently led by Dr. Don Davis, a Center consultant, is about to lose its funding. The Biocommunications Research Institute will take steps to transfer and preserve the technology and data developed.

We will send one of our scientists to Austin, Texas to learn the experimental techniques involved in measuring lymphocyte metabolism. We can then evaluate these techniques to determine if they warrant further study by our institute. In addition, we will fund a comprehensive statistical review, to be conducted by Dr. Davis, of lymphocyte metabolism data as it relates to disorders such as neural tube defects. Finally, we will fund the transfer of the Clayton Research Institute's experimental records (data and protocols), representing over fifteen years worth of research, from Texas to our Institute.

YEAR 2002 RESEARCH → YEAR END REPORT

Goal 18) *To have evaluated, by the end of 2003, the diagnostic utility of techniques developed by the Clayton Research Institute to measure lymphocyte metabolism.*

Goal 19) *To complete the analysis and transfer of data from the Clayton Research Institute to the Biocommunications Research Institute by the end of 2003.*

■ On Hold

We are happy to report that the Clayton Research Institute has won a funding extension to the end of 2003. Hence, we will not need to transfer their technology and data to our facility at this time. However, Dr. Xiao Long Meng did visit the Institute's laboratory last summer and has learned some of their experimental techniques.

Spectral Analysis

In the past, we have shown that the intensity of serum fluorescence at certain wavelengths is proportional to the concentration of NADH, an important oxidation/reduction agent. We believe this to be an indicator of overall energy metabolism, and find variation in NADH levels with disease. In short, measurements of serum fluorescence may prove valuable in diagnosis and in following progress during treatment. We are collaborating with Dr. Paul Rillema at Wichita State University to continue characterizing this technology. In the next two years, we want to patent the process and publish our results. In addition, we would like to obtain more data in order to assess how NADH levels vary with health and illness.

Goal 20) *To have obtained a patent for the serum fluorescence procedure and to have submitted a manuscript describing it to a peer-reviewed journal by the end of 2003.*

Goal 21) *To continue to collect data from a wide variety of co-learners so their NADH levels can be compared to normal ranges determined for staff volunteers.*

☺ Completed: positive results

We have submitted two manuscripts concerning our use of serum fluorescence data to ascertain NADH levels and overall 'energy status'. We have continued to collect serum fluorescence data from patients and healthy volunteers. Among our conclusions thus far

- Serum fluorescence correlates with variables such as coenzyme Q10 concentration, urine pyrrole levels, antioxidant concentrations, red blood cell counts, hemoglobin levels, and the presence of the tumor marker CEA.

YEAR 2002 RESEARCH → YEAR END REPORT

- We find that the mean serum fluorescence values observed cancer patients or chronic fatigue syndrome sufferers differ significantly from those in healthy adults.

In 2003, we hope to expand upon this work by using more sophisticated methods to analyze serum spectra.

We have recently developed fluorescence-based techniques for measuring the metabolic and phagocytic activity of white blood cells. We would like to assess the sensitivity of this assay and, if it is sufficiently accurate, use it to measure the effects of ascorbate therapy on immune cell function (see goals 2 and 3 above). Finally, we will continue to explore new spectral techniques for assessing human functioning.

Goal 22) *To determine the sensitivity and accuracy of our lymphocyte activity assay, comparing values obtained with the health of the donor and with other assays for white cell activity.*

☺ Completed: positive results

We developed a protocol for measuring granulocytes activity based on NADPH oxidase activity and hydrogen peroxide generation. We were able to demonstrate that granulocytes activity in patients with cancer and diabetes is significantly below normal, while patients with arthritis or viral infections show elevated granulocytes activities.

We also used this technique to assess the effect of vitamin C on granulocytes activity, but we found no significant effect. We thus suspect that the role of this antioxidant in granulocytes health relates to its ability to neutralize oxidants that might otherwise harm the white blood cells.

To complement this research, we also began developing assays to measure mitochondrial potential and mitochondria concentrations in white blood cells. This will not only give us another tool with which to assess white blood cell activity, but will perhaps be useful to Dr. Gonzales in his studies of tumor cell energetics (see above). In 2003, we hope to start a clinical study examining the effect of a flax based supplement on mitochondrial activity in staff volunteers.

Microscopy

The Biocommunications Research Institute has been long interested in the use of microscopic techniques, including the use of dark-field microscopy to examine 'inclusion bodies' in red blood cells, as tools for

YEAR 2002 RESEARCH → YEAR END REPORT

diagnosis We have recently learned of the LC-Polscope, a device that enhances the detection of sub-cellular structures with light microscopy by polarizing light in a particular way We would like to purchase this equipment and then use it to investigate phenomenon such as the 'flicker' that is observed in the red blood cells of unhealthy people, and also to explore how subtle energies affect cells.

Goal 23) *To obtain, set up, and learn how to use an LC-Polscope system by the end of 2002.*

Goal 24) *To use the polscope, or other microscopic techniques, to examine cellular features of cells that may be of diagnostic use, including red blood cell 'flickering', 'inclusion bodies', white blood cells before and after stimuli, and the difference between cancer cells and normal cells.*

Goal 25) *To use the polscope, or other microscopic techniques, to examine how cell structure is affected by subtle energies and frequencies such as sound waves.*

■ On Hold

We have not yet purchased a LC-Polscope, primarily because we do not at present have the personnel to utilize it. This will change in 2003, as not only does the Biocommunications Research Institute plan to hire more scientists, but also the Center's decision to hire new physicians will give Dr. Hugh Riordan more time to devote to this project.

Information Processing

We are hoping to develop methods for storing, displaying, and consolidating patient history and lab test data in ways that enhance physician diagnosis This includes developing a Gestalt database that will display patient histories in a color-coded format and creating a database of cancer patients

Goal 26) *To have entered data from 100 co-learners into the current Gestalt database by the end of 2002. This will allow the program to be assessed and modified according to physician needs.*

Goal 27) *To have, by the end of 2003, a Gestalt system in place that can be used with other programs to pull up and sort patient history and lab test results.*

⚙ Significant Progress

The previous year saw substantial improvements in our Gestalt program. In particular, a much smoother menu system for data entry has been put into place. We have currently entered patient history data for over 100 co-learners. All that remains is to finish entering the lab test

YEAR 2002 RESEARCH → YEAR END REPORT

results for these patients. Once this data entry is complete, we will evaluate the program and, if necessary, we modify its format for displaying data.

We have also taken the first steps in updating the Gestalt program so that it can read data from Excel files generated by our new lab data management program. This should be completed by the end of 2003.

Other Diagnostic Research

The Biocommunications Research Institute, to the extent to which financial resources enable it to, will pursue goals other than those listed above.

Goal 28) *To continue our research into the potential diagnostic power of Kirlian photography.*

Goal 29) *To continue research with brain mapping.*

Goal 30) *To examine the effects of food allergies on cellular cytokine production in patients with rheumatoid arthritis.*

■ On Hold

These projects have not become a priority for the Biocommunications Research Institute. In the coming year, we plan to replace them with the following:

- Clinical studies concerning the effects of intravenous vitamin C and trace mineral supplementation on cataracts and macular degeneration.
 - Microscopic studies into the effects of various antigens on the morphology and function of white blood cells.
 - Clinical studies examining the effect of whole food supplements on behavioral problems in school children.
 - Research into the effect of subtle energies, including sound and magnetism, on cell morphology and function.
 - Clinical studies into the effects of hyperbaric oxygenation on patients with chronic fatigue syndrome or long-term viral infections. This work will include measurements of serum fluorescence and mitochondrial function as described above.
-

THE CENTER FOR THE IMPROVEMENT OF
HUMAN FUNCTIONING INTERNATIONAL, INC
DECEMBER 31, 2002

48-0840415

SCHEDULE 2

Schedule A, Form 990, Part III, Line 2 (d)

Dr Hugh D Riordan, M D is the President of The Center for the Improvement of Human Functioning International, Inc He is involved with the solicitation of funds and grants, budgets of these funds, and is the Director of the Bio-Communications Research Institute The position requires current knowledge in multiple fields of study Therefore, Dr Riordan is required to attend seminars in various locations throughout the country and meet with researchers around the world The cost of travel, meals, lodging, and seminar fees that are incurred by Dr Riordan are paid by The Center or are reimbursed to him All honoraria are paid to The Center with none accruing to the financial benefit of Dr Riordan

In addition to the above stated activities, Dr Riordan devotes a significant amount of time to presenting on-going seminars and conferences These conferences are designed to communicate new directions for research and treatment that are presented to the medical and health-related professions

Asset Depreciation Short Report - Sorted by - ASSET A/C#

Company THE CENTER FOR THE IMPROV OF HUMAN FUNC Year End 12/31/02
 Method 1 - FEDERAL Std Conv Applied File C:\AKDATA\CENTER
 Range 140 - OFFICE EQUIPMENT - 175 - LAND & MASTER FACILITY Include All assets

Date Acq	Description	Meth/Life	Cost	Sec 179	Depr Basis	Includes Section 179		
						Beg A/Depr	Curr Depr	End A/Depr
ASSET A/C# 140 - OFFICE EQUIPMENT								
07/01/80	OFFICE EQUIP	SLP/ 8 00	74 872 59	0 00	74 872 59	74 872 59	0 00	74 872 59
07/01/81	OFFICE EQUIP	SLP/ 8 00	97 048 71	0 00	97 048 71	97 048 71	0 00	97,048 71
07/01/82	OFFICE EQUIP	SLP/ 8 00	50 478 67	0 00	50,478 67	50,478 67	0 00	50,478 67
07/01/83	OFFICE EQUIP	SLP/ 8 00	28,653 09	0 00	28 653 09	28,653 09	0 00	28 653 09
07/01/84	OFFICE EQUIP	SLP/ 8 00	38,735 00	0 00	38,735 00	38,735 00	0 00	38 735 00
07/01/85	OFFICE EQUIP	SLP/ 8 00	38 192 39	0 00	38 192 39	38 192 39	0 00	38,192 39
07/01/86	OFFICE EQUIP	SLP/ 8 00	77,160 79	0 00	77,160 79	77,160 79	0 00	77 160 79
07/01/87	OFFICE EQUIP	SLP/ 8 00	25,566 94	0 00	25,566 94	25 566 94	0 00	25,566 94
07/01/88	OFFICE EQUIP	SLP/ 8 00	71 348 39	0 00	71 348 39	71 348 39	0 00	71,348 39
07/01/89	OFFICE EQUIP	SLP/ 8 00	21,072 07	0 00	21,072 07	21,072 07	0 00	21 072 07
07/01/90	OFFICE EQUIP	SLP/ 8 00	2,993 65	0 00	2,993 65	2 993 65	0 00	2 993 65
07/01/91	OFFICE EQUIP	SLP/ 8 00	2 641 96	0 00	2,641 96	2 641 96	0 00	2 641 96
07/01/92	OFFICE EQUIP	SLP/ 8 00	17 678 58	0 00	17 678 58	17,678 58	0 00	17,678 58
07/01/93	OFFICE EQUIP	SLP/ 8 00	7,195 08	0 00	7,195 08	7,195 08	0 00	7 195 08
07/01/94	OFFICE EQUIP	SLP/ 8 00	8 386 50	0 00	8,386 50	7 862 33	524 17	8 386 50
07/01/95	OFFICE EQUIP	SLP/ 8 00	25,911 65	0 00	25 911 65	21,053 24	3,238 96	24,292 20
07/01/96	OFFICE EQUIP	SLP/ 8 00	55,766 80	0 00	55,766 80	38,353 43	6 973 35	45 326 78
07/01/97	OFFICE EQUIPMENT	SLP/ 8 00	14,202 45	0 00	14,202 45	7 988 89	1,775 31	9 764 20
07/01/98	OFFICE EQUIPMENT	SLP/ 8 00	23 935 33	0 00	23 935 33	10,471 72	2 891 92	13,463 64
07/01/99	OFFICE EQUIPMENT	SLP/ 8 00	72 796 19	0 00	72 796 19	22,748 80	9 099 52	31 848 32
07/01/00	OFFICE EQUIPMENT	SLP/ 8 00	21,460 55	0 00	21 460 55	4 023 85	2 682 57	6 708 42
07/01/01	OFFICE EQUIPMENT	SLP/ 8 00	41,566 98	0 00	41 566 98	2,597 94	5 195 87	7 793 81
07/01/02 A	OFFICE EQUIPMENT	SLP/ 8 00	76 470 66	0 00	76,470 66	0 00	4 779 42	4 779 42
Grand totals 140 - OFFICE EQUIPMENT (23 assets)			693,953 02	0 00	693 953 02	668,536 11	37 261 09	705 797 20
ASSET A/C# 142 - OTHER EQUIPMENT								
07/01/84	OTHER EQUIP	SLP/ 8 00	14,262 00	0 00	14 262 00	14,262 00	0 00	14 262 00
08/01/84	TELE SYSTEM	SLP/ 8 00	32 873 74	0 00	32,873 74	32 873 74	0 00	32 873 74
07/01/85	OTHER EQUIP	SLP/ 8 00	27 139 61	0 00	27,139 61	27 139 61	0 00	27 139 61
07/01/86	OTHER EQUIP	SLP/ 8 00	6,616 89	0 00	6 616 89	6,616 89	0 00	6,616 89
07/01/87	OTHER EQUIP	SLP/ 8 00	12 592 47	0 00	12,592 47	12 592 47	0 00	12 592 47
07/01/88	OTHER EQUIP	SLP/ 8 00	4 807 97	0 00	4,807 97	4,807 97	0 00	4 807 97
07/01/89	OTHER EQUIP	SLP/ 8 00	6,948 79	0 00	6,948 79	6 948 79	0 00	6 948 79
07/01/90	OTHER EQUIP	SLP/ 8 00	5 304 30	0 00	5 304 30	5,304 30	0 00	5,304 30
07/01/91	OTHER EQUIP	SLP/ 8 00	515 51	0 00	515 51	515 51	0 00	515 51
07/01/92	OTHER EQUIP	SLP/ 8 00	4,572 74	0 00	4 572 74	4 572 74	0 00	4 572 74
07/01/93	OTHER EQUIP	SLP/ 8 00	4 894 94	0 00	4 894 94	4 894 94	0 00	4 894 94
Grand totals 142 - OTHER EQUIPMENT (11 assets)			120 528 96	0 00	120 528 96	120 528 96	0 00	120 528 96
ASSET A/C# 144 - MEDICAL EQUIPMENT								
07/01/76	LAB EQUIP	SLP/ 8 00	74,393 44	0 00	74 393 44	74 393 44	0 00	74 393 44
07/01/77	LAB EQUIP	SLP/ 8 00	3 664 02	0 00	3,664 02	3 664 02	0 00	3,664 02
07/01/78	LAB EQUIP	SLP/ 8 00	508 48	0 00	508 48	508 48	0 00	508 48
07/01/79	LAB EQUIP	SLP/ 8 00	52 722 29	0 00	52,722 29	52,722 29	0 00	52 722 29
07/01/80	LAB EQUIP	SLP/ 8 00	61 189 80	0 00	61 189 80	61 189 80	0 00	61 189 80
07/01/81	LAB EQUIP	SLP/ 8 00	103 710 25	0 00	103 710 25	103,710 25	0 00	103,710 25
07/01/82	LAB EQUIP	SLP/ 8 00	12 626 79	0 00	12,626 79	12 626 79	0 00	12 626 79
07/01/83	LAB EQUIP	SLP/ 8 00	6 477 67	0 00	6,477 67	6 477 67	0 00	6,477 67
07/01/84	LAB EQUIP	SLP/ 8 00	4 186 43	0 00	4,186 43	4,186 43	0 00	4,186 43
07/01/85	LAB EQUIP	SLP/ 8 00	44 334 32	0 00	44,334 32	44,334 32	0 00	44 334 32
07/01/86	LAB EQUIP	SLP/ 8 00	83 475 92	0 00	83 475 92	83 475 92	0 00	83 475 92
07/01/87	LAB EQUIP	SLP/ 8 00	12,409 89	0 00	12,409 89	12 409 89	0 00	12,409 89
07/01/88	LAB EQUIP	SLP/ 8 00	50 812 98	0 00	50 812 98	50,812 98	0 00	50,812 98
07/01/89	LAB EQUIP	SLP/ 8 00	40,656 90	0 00	40 656 90	40 656 90	0 00	40 656 90
07/01/90	LAB EQUIP	SLP/ 8 00	12 045 21	0 00	12,045 21	12,045 21	0 00	12 045 21
07/01/90	GAMMA COUNTER	SLP/ 8 00	14,000 00	0 00	14 000 00	14,000 00	0 00	14,000 00
07/01/90	COBAS	SLP/ 8 00	31,121 00	0 00	31 121 00	31,121 00	0 00	31,121 00
07/01/91	LAB EQUIP	SLP/ 8 00	29 183 94	0 00	29,183 94	29 183 94	0 00	29 183 94

Asset Depreciation Short Report - Sorted by ASSET A/C#

Company THE CENTER FOR THE IMPROV OF HUMAN FUNC

Year End 12/31/02

Method 1 - FEDERAL

Date 05/09/03

Date Acq	Description	Meth/Life	Cost	Sec 179	Depr Basis	Includes Section 179		
						Beg A/Depr	Curr Depr	End A/Depr
ASSET A/C# 144 - MEDICAL EQUIPMENT								
07/01/91	ISE	SLP/ 8 00	7 000 00	0 00	7,000 00	7 000 00	0 00	7,000 00
07/01/91	MINOS	SLP/ 8 00	23 200 00	0 00	23 200 00	23,200 00	0 00	23 200 00
07/01/91	VARIAN	SLP/ 8 00	28,454 00	0 00	28 454 00	28 454 00	0 00	28 454 00
07/01/92	LAB EQUIP	SLP/ 8 00	156 030 00	0 00	156,030 00	156 030 00	0 00	156 030 00
07/01/93	LAB EQUIP	SLP/ 8 00	26,502 67	0 00	26 502 67	26 502 67	0 00	26 502 67
07/01/94	LAB EQUIP	SLP/ 8 00	50,902 90	0 00	50 902 90	47,721 45	3,181 45	50 902 90
07/01/95	LAB EQUIP	SLP/ 8 00	65 633 50	0 00	65 633 50	53 327 23	8 204 19	61,531 42
07/01/96	LAB EQUIP	SLP/ 8 00	288,498 19	0 00	288,498 19	198 342 49	38,062 27	234 404 78
07/01/97	LAB EQUIP	SLP/ 8 00	293 345 77	0 00	293,345 77	165,007 00	38 668 22	201 675 22
07/01/98	LAB EQUIPMENT	SLP/ 8 00	150,172 89	0 00	150,172 89	65,700 63	18 771 61	84 472 24
07/01/99	LAB EQUIPMENT	SLP/ 8 00	124 954 42	0 00	124 954 42	39,048 25	15,819 30	54 667 55
07/01/00	LAB EQUIPMENT	SLP/ 8 00	78 720 49	0 00	78,720 49	14,760 09	9,840 06	24 600 15
07/01/01	LAB EQUIPMENT	SLP/ 8 00	181 397 87	0 00	181 397 87	11,337 37	22,874 73	34 012 10
07/01/02 A	LAB EQUIPMENT	SLP/ 8 00	139,344 62	0 00	139,344 62	0 00	8 709 04	8 709 04
Grand totals 144 - MEDICAL EQUIPMENT (32 assets)			2,251,676 63	0 00	2 251 676 63	1 473 950 49	159,730 87	1 633,681 38
ASSET A/C# 147 - VEHICLES								
10/01/85	TURF MAINT MACH	SLP/ 3 00	4 020 00	0 00	4 020 00	4,020 00	0 00	4,020 00
07/01/92	1991 COLT	SLP/ 3 00	7,942 50	0 00	7,942 50	7,942 50	0 00	7,942 50
06/02/01	1992 TRUCK	SLP/ 3 00	4,009 90	0 00	4,009 90	779 70	1 336 63	2 116 33
Grand totals 147 - VEHICLES (3 assets)			15,972 40	0 00	15 972 40	12,742 20	1,336 63	14 078 83
ASSET A/C# 171 - LAND IMPROVEMENTS								
07/01/85	LANDSCAPING	SLP/ 8 00	8 817 09	0 00	8 817 09	8,817 09	0 00	8 817 09
07/01/88	LANDSCAPING	SLP/ 8 00	19,656 55	0 00	19 656 55	19 656 55	0 00	19 656 55
07/01/87	LANDSCAPING	SLP/ 8 00	1,584 50	0 00	1,584 50	1,584 50	0 00	1,584 50
07/01/88	LANDSCAPING	SLP/ 8 00	2 084 38	0 00	2 084 38	2 084 38	0 00	2 084 38
07/01/89	LANDSCAPING	SLP/ 8 00	2,294 73	0 00	2,294 73	2 294 73	0 00	2 294 73
07/01/97	LANDSCAPING	SLP/ 8 00	296 52	0 00	296 52	166 81	37 07	203 88
Grand totals 171 - LAND IMPROVEMENTS (6 assets)			34 713 77	0 00	34,713 77	34 584 08	37 07	34 621 13
ASSET A/C# 175 - LAND & MASTER FACILITY								
07/01/81	LAND	NONE/ 0 01	248 411 57	0 00	0 00	0 00	0 00	0 00
11/28/83	LAND	NONE/ 0 00	38 450 00	0 00	0 00	0 00	0 00	0 00
07/01/84	LAND	NONE/ 0 00	15,867 15	0 00	0 00	0 00	0 00	0 00
08/01/84	MASTER FACILITY	ACRS/18 00	3,575 448 15	0 00	3 575,448 15	3,110 639 92	143 017 93	3 253 657 85
07/01/93	MASTER FACILITY	SLP/25 00	209 069 31	0 00	209,069 31	71,083 55	8 362 77	79 446 32
07/01/94	MASTER FACILITY	SLP/25 00	11 314 35	0 00	11 314 35	3,394 28	452 57	3 846 85
07/01/96	MASTER FACILITY	SLP/25 00	63 775 78	0 00	63 775 78	14,030 67	2,551 03	16 581 70
07/01/97	MASTER FACILITY	SLP/25 00	24 876 31	0 00	24 876 31	4,477 73	895 05	5,472 78
11/01/97	MASTER FACILITY	SLP/25 00	1,851 69	0 00	1,851 69	308 62	74 07	382 69
12/01/97	MASTER FACILITY	SLP/25 00	1 433 63	0 00	1,433 63	234 18	57 35	291 53
03/10/98	MASTER FACILITY	SLP/25 00	866 26	0 00	866 26	132 83	34 65	167 48
06/01/98	MASTER FACILITY	SLP/25 00	2,718 34	0 00	2,718 34	389 33	108 65	497 98
06/22/98	MASTER FACILITY	SLP/25 00	2 484 46	0 00	2,484 46	353 24	98 58	451 82
06/22/98	MASTER FACILITY	SLP/25 00	3 087 47	0 00	3,087 47	442 54	123 50	566 04
07/20/98	MASTER FACILITY	SLP/25 00	9 101 04	0 00	9 101 04	1,274 14	364 04	1 638 18
09/20/98	MASTER FACILITY	SLP/25 00	2 857 18	0 00	2,857 18	380 97	114 29	495 26
10/21/98	MASTER FACILITY	SLP/25 00	478 15	0 00	478 15	62 17	19 13	81 30
11/20/98	MASTER FACILITY	SLP/25 00	799 09	0 00	799 09	101 21	31 98	133 17
07/01/99	MASTER FACILITY	SLP/25 00	52,279 59	0 00	52 279 59	5,227 85	2,091 18	7,319 13
07/01/00	MASTER FACILITY	SLP/25 00	106,584 53	0 00	106 584 53	6 393 87	4 262 58	10 656 45
07/01/01	MASTER FACILITY	SLP/25 00	28 207 06	0 00	28,207 06	564 14	1 128 28	1,692 42
07/01/02 A	MASTER FACILITY	SLP/25 00	66,161 31	0 00	66 161 31	0 00	1,323 23	1 323 23
Grand totals 175 - LAND & MASTER FACILITY (22 assets)			4 464 080 42	0 00	4 163,351 70	3,219,491 34	165,210 84	3,384 702 18

Asset Depreciation Short Report - Sorted by ASSET A/C#

*Company THE CENTER FOR THE IMPROV OF HUMAN FUNC * Year End 12/31/02 Method 1 - FEDERAL

Date Acq	Description	Meth/Life	Cost	Sec 179	Depr Basis	Includes Section 179		
						Beg A/Depr	Curr Depr	End A/Depr
Grand totals for all accounts (97 assets)			7,780,925 20	0 00	7,480,196 48	5,529 833 18	363 576 50	5 893,409 66

Codes that may appear next to the date acquired include A - Addition, D - Disposal, T - Traded, MQ - Mid Quarter Applied

Additional Summary Statistics for Assets

	Cost	Current Year Section 179	Depreciable Basis	Beginning Accum Depr	Current Depreciation	Ending Accum Depr	Net Book Value
Grand Totals for all assets	7 780 925 20	0 00	7 480,196 48	5,529 833 18	363,576 50	5 893,409 66	1 887 515 54
Less Inactive Assets	0 00	0 00	0 00	0 00	0 00	0 00	0 00
Disposed Assets	0 00	0 00	0 00	0 00	0 00	0 00	0 00
Traded Assets	0 00	0 00	0 00	0 00	0 00	0 00	0 00
Net Totals (Active Assets)	7,780 925 20	0 00	7,480,196 48	5,529,833 18	363,576 50	5 893 409 66	1,887 515 54